Information Provided By: 
Fly News Breaks for May 23, 2019
PFE, ALNY
May 23, 2019 | 06:30 EDT
Goldman Sachs analyst Salveen Richter assumed coverage of Alnylam Pharmaceuticals (ALNY) with a Neutral rating and $80 price target. The firm previously had a Buy rating on the shares. Onpattro, Alnylam's first commercial drug and key value driver, had a positive launch start, but anticipated competitive headwinds from recently approved Pfizer's tafamidis are an overhang on the shares, Richter tells investors in a research note. The analyst is on the sidelines as he assesses the drug's competitive landscape.
News For ALNY;PFE From the Last 2 Days
PFE
Apr 25, 2024 | 10:25 EDT
Bullish option flow detected in Pfizer with 50,393 calls trading, 2x expected, and implied vol increasing over 2 points to 28.83%. Sep-24 27.5 calls and Mar-25 42.5 calls are the most active options, with total volume in those strikes near 27,600 contracts. The Put/Call Ratio is 0.21. Earnings are expected on May 1st.
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
